Seike Yoshimasa, Matsuda Hitoshi, Fukuda Tetsuya, Hori Yoshiro, Inoue Yosuke, Omura Atsushi, Uehara Kyokun, Sasaki Hiroaki, Kobayashi Junjiro
Department of Cardiovascular Surgery, National Cerebral and Cardiovascular Center, Osaka, Japan.
Department of Radiology, National Cerebral and Cardiovascular Center, Osaka, Japan.
Interact Cardiovasc Thorac Surg. 2019 Jul 1;29(1):101-108. doi: 10.1093/icvts/ivz027.
This study aimed to assess differences in midterm outcomes between total arch replacement (TAR) and debranching thoracic endovascular aortic repair (d-TEVAR) and to evaluate the validity of d-TEVAR as the preferred treatment choice for aortic arch aneurysm in the elderly.
We reviewed the case histories of 86 patients who had undergone TAR (64 men; mean age 78 ± 2.9 years) and 121 patients who had undergone d-TEVAR (90 men; mean age 82 ± 4.5 years) between 2007 and 2017; of these patients, 50 from each group were matched based on propensity scores to adjust for differences in patient characteristics.
Rates of freedom from all-cause mortality at 2 and 4 years were similar between the 2 groups (88% and 77% in the TAR group vs 82% and 64% in the d-TEVAR group, P = 0.11), but rates of freedom from reintervention at 2 and 4 years were significantly higher in the TAR group (100% and 96%) than in the d-TEVAR group (97% and 88%) (P = 0.004). Propensity score matching yielded similar survival rates of 88% and 85% for TAR vs 86% and 71% for d-TEVAR (P = 0.53) and comparable freedom from reintervention rates (100% and 97% in TAR, 98% and 90% in d-TEVAR, P = 0.16) at 2 and 4 years. Cox regression analysis identified previous cerebral infarction [hazard ratio (HR) 3.9; P = 0.005 in TAR/HR 3.1; P = 0.002 in d-TEVAR] as an independent positive predictor of overall mortality in both groups.
Midterm outcomes after TAR and d-TEVAR were satisfactory and propensity score matching-based evaluation revealed no significant differences in outcomes, implying that d-TEVAR is an acceptable first-choice procedure for aortic arch aneurysm in patients older than 75 years.
本研究旨在评估全弓置换术(TAR)和去分支胸主动脉腔内修复术(d-TEVAR)的中期疗效差异,并评估d-TEVAR作为老年主动脉弓动脉瘤首选治疗方法的有效性。
我们回顾了2007年至2017年间接受TAR的86例患者(64例男性;平均年龄78±2.9岁)和接受d-TEVAR的121例患者(90例男性;平均年龄82±4.5岁)的病历;其中,每组50例患者根据倾向评分进行匹配,以调整患者特征的差异。
两组在2年和4年时的全因死亡率无差异(TAR组为88%和77%,d-TEVAR组为82%和64%,P=0.11),但TAR组在2年和4年时的再次干预率显著高于d-TEVAR组(分别为100%和96% vs 97%和88%)(P=0.004)。倾向评分匹配后,TAR组和d-TEVAR组的生存率相似,分别为88%和85% vs 86%和71%(P=0.53),2年和4年时的再次干预率也相当(TAR组为100%和97%,d-TEVAR组为98%和90%,P=0.16)。Cox回归分析确定既往脑梗死为两组总体死亡率的独立阳性预测因素(TAR组风险比[HR] 3.9;P=0.005/d-TEVAR组HR 3.1;P=0.002)。
TAR和d-TEVAR后的中期疗效令人满意,基于倾向评分匹配的评估显示疗效无显著差异,这意味着d-TEVAR是75岁以上主动脉弓动脉瘤患者可接受的首选手术。